Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Lucid Group Inc (LCID) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Lucid Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Lucid Group Inc trades at $5.98 (market cap $2.34B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | LCID | |
|---|---|---|
Market Cap | $4.49B | $2.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $31.30 |
52-Week Low | $20.06 | $4.70 |
Enterprise Value | $3.69B | $4.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Lucid Group (LCID) trades at $5.995, down 1.4% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 deliveries of 3,093 vehicles, missing expectations, alongside a leadership overhaul. Financially, LCID shows severe losses with a net income margin of -239.81% in 2025 and negative cash flow from operations of -$2.93B, though revenue grew to $1.35B.
The outlook remains challenging due to persistent losses and high cash burn, but the consensus price target of $11.75 suggests potential upside if execution improves. Key risks include ongoing class-action lawsuits, competitive pressures in the EV market, and reliance on Saudi funding. Investors should weigh the high-risk profile against long-term growth prospects in electric vehicles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
